Mitoses Counted with Digital Pathology in Breast Phyllodes Tumors
By LabMedica International staff writers Posted on 26 Nov 2020 |

Image: IntelliSite Ultra-Fast Digital pathology slide scanner is designed to accommodate current histopathology needs for routine use in high volume labs and integrated pathology networks (Photo courtesy of Philips Digital Pathology Solutions).
Phyllodes tumors (PTs) are a fibroepithelial tumor composed of an epithelial and a cellular stromal component. They may be considered benign, borderline, or malignant depending on histologic features including stromal cellularity, infiltration at the tumor's edge, and mitotic activity.
Digital pathology (DP) is becoming more widely available and has been harnessed to enhance diagnosis and access to subspecialty opinion, promote education, and may also be deployed for remote reporting. DP has enabled the development of artificial intelligence (AI) in pathology, through image analysis and machine learning, including working toward open source access.
Pathologists at the Singapore General Hospital (Singapore) and their colleagues chose representative slides from 93 cases of PTs diagnosed between 2014 and 2015. The mean age ± SD of the cohort was 42.5 ± 12.7 years. Of these, 60 were benign, 31 borderline, and two malignant, which were graded based on the World Health Organization guidelines. Specifically, stromal hypercellularity and stromal atypia were categorized into mild, moderate, and marked, according to the consensus review.
The slides were scanned with the IntelliSite Ultra-Fast Scanner (Philips Digital Pathology Solutions, Eindhoven, the Netherlands) and viewed with the Philips’ Image Management System viewer. Mitotic counting was conducted on the whole slide image, before choosing 10 high powered fields (HPFs) and demarcating the tumor area in DP. Values of mitoses/mm2 were used to compare results between 10 HPFs and the whole slide. Correlations with clinicopathological parameters were conducted.
The scientists reported that in terms of atypia, 65 (70.0%) PT cases displayed mild atypia, followed by 27 (29.0%) moderate atypia and one (1%) marked atypia. For stromal cellularity, 50 (53.8%) tumors displayed moderate hypercellularity, followed by 31 (33.3%) mild hypercellularity and 12 (12.9%) marked hypercellularity. The mean size of the tumors was 4.6 ± 3.3 cm3 (mean ± SD cm3). Both whole slide counting of mitoses and 10 HPFs had similar statistically significant correlation coefficients with grade, stromal atypia, and stromal hypercellularity. Neither whole slide mitotic counts nor mitoses per 10 HPFs showed statistically significant correlations with patient age and tumor size.
The authors concluded that an accurate set of 10 HPFs that yielded a maximal mitotic count can be chosen after evaluating the whole slide. DP makes counting mitoses over a larger area subjectively easier, with the possibility of AI being used as facilitator and enabler. This could influence how to approach training, testing, and validation of future AI algorithms for mitotic counting. The study was published in the November. 2020 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Singapore General Hospital
Philips Digital Pathology Solutions
Digital pathology (DP) is becoming more widely available and has been harnessed to enhance diagnosis and access to subspecialty opinion, promote education, and may also be deployed for remote reporting. DP has enabled the development of artificial intelligence (AI) in pathology, through image analysis and machine learning, including working toward open source access.
Pathologists at the Singapore General Hospital (Singapore) and their colleagues chose representative slides from 93 cases of PTs diagnosed between 2014 and 2015. The mean age ± SD of the cohort was 42.5 ± 12.7 years. Of these, 60 were benign, 31 borderline, and two malignant, which were graded based on the World Health Organization guidelines. Specifically, stromal hypercellularity and stromal atypia were categorized into mild, moderate, and marked, according to the consensus review.
The slides were scanned with the IntelliSite Ultra-Fast Scanner (Philips Digital Pathology Solutions, Eindhoven, the Netherlands) and viewed with the Philips’ Image Management System viewer. Mitotic counting was conducted on the whole slide image, before choosing 10 high powered fields (HPFs) and demarcating the tumor area in DP. Values of mitoses/mm2 were used to compare results between 10 HPFs and the whole slide. Correlations with clinicopathological parameters were conducted.
The scientists reported that in terms of atypia, 65 (70.0%) PT cases displayed mild atypia, followed by 27 (29.0%) moderate atypia and one (1%) marked atypia. For stromal cellularity, 50 (53.8%) tumors displayed moderate hypercellularity, followed by 31 (33.3%) mild hypercellularity and 12 (12.9%) marked hypercellularity. The mean size of the tumors was 4.6 ± 3.3 cm3 (mean ± SD cm3). Both whole slide counting of mitoses and 10 HPFs had similar statistically significant correlation coefficients with grade, stromal atypia, and stromal hypercellularity. Neither whole slide mitotic counts nor mitoses per 10 HPFs showed statistically significant correlations with patient age and tumor size.
The authors concluded that an accurate set of 10 HPFs that yielded a maximal mitotic count can be chosen after evaluating the whole slide. DP makes counting mitoses over a larger area subjectively easier, with the possibility of AI being used as facilitator and enabler. This could influence how to approach training, testing, and validation of future AI algorithms for mitotic counting. The study was published in the November. 2020 issue of the journal Archives of Pathology and Laboratory Medicine.
Related Links:
Singapore General Hospital
Philips Digital Pathology Solutions
Latest Pathology News
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
- First-Of-Its-Kind AI Tool Visualizes Cell’s ‘Social Network’ To Treat Cancer
- New Test Diagnoses High-Risk Childhood Brain Tumors
- Informatics Solution Elevates Laboratory Efficiency and Patient Care
- Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more